celecoxib has been researched along with Gastric Ulcer in 81 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A lower incidence of gastric and duodenal ulcers was seen in celecoxib/aspirin-treated subjects (19%) vs." | 9.12 | The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. ( Dodge, WE; Goldstein, JL; Lanza, FL; Lowry, SC; Schwartz, HI, 2006) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 8.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs)." | 7.78 | Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. ( Edogawa, S; Hamada, M; Hirata, Y; Iguchi, M; Kawai, H; Miyoshi, H; Nakase, T; Oomae, T; Tomita, T; Tsuji, S; Tsumoto, C; Yoshikawa, H, 2012) |
| "The mechanism of indomethacin-induced gastric ulcer healing by ellagic acid (EA) in experimental mice model is described in our study." | 7.78 | Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. ( Bandyopadhyay, SK; Chatterjee, A; Chatterjee, S; Chattopadhyay, S; Das, S; Saha, A, 2012) |
| "To determine the rate of endoscopic gastric/duodenal ulcers (GDUs) associated with use of aspirin (81 mg q." | 5.13 | Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial. ( Aisenberg, J; Berger, MF; Dodge, WE; Goldstein, JL; Zakko, SF, 2008) |
| "A lower incidence of gastric and duodenal ulcers was seen in celecoxib/aspirin-treated subjects (19%) vs." | 5.12 | The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. ( Dodge, WE; Goldstein, JL; Lanza, FL; Lowry, SC; Schwartz, HI, 2006) |
| "Subjects 18 years or older with osteoarthritis, without gastroduodenal ulcer or erosive esophagitis at baseline endoscopy, and a cardiovascular indication for prophylaxis low-dose (81 or 325 mg) aspirin were prescribed open-label aspirin and blindly randomized to celecoxib 200 mg/day or naproxen 500 mg twice daily plus lansoprazole 30 mg once daily." | 5.12 | Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. ( Amer, F; Cryer, B; Goldstein, JL; Hunt, B, 2007) |
| " In the upper GI endoscopy study, 19% of subjects receiving naproxen (6 of 32) developed gastric ulcers, whereas no ulcers occurred in subjects receiving SC-58635 or placebo." | 5.08 | Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. ( Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S, 1998) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 4.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "We previously reported that 2-fluoroloxoprofen has lower gastric ulcerogenic activity than loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID) without selectivity for COX-2." | 3.78 | Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity. ( Asano, T; Ishihara, T; Miyata, K; Mizushima, T; Okamoto, Y; Otsuka, M; Suemasu, S; Tanaka, K; Yamakawa, N, 2012) |
| "We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.78 | Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. ( Edogawa, S; Hamada, M; Hirata, Y; Iguchi, M; Kawai, H; Miyoshi, H; Nakase, T; Oomae, T; Tomita, T; Tsuji, S; Tsumoto, C; Yoshikawa, H, 2012) |
| "The mechanism of indomethacin-induced gastric ulcer healing by ellagic acid (EA) in experimental mice model is described in our study." | 3.78 | Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. ( Bandyopadhyay, SK; Chatterjee, A; Chatterjee, S; Chattopadhyay, S; Das, S; Saha, A, 2012) |
| "Rodent models were employed to investigate the effects of combinations of celecoxib and aspirin on gastric ulcerogenesis, bleeding, surface hydrophobicity (by contact angle analysis) and ulcer healing." | 3.74 | Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. ( Dial, EJ; Lichtenberger, LM; Romero, JJ, 2007) |
| "Selective COX-2 inhibitor can significantly delay the healing of experimental gastric ulcer in rats, the mechanism of which might be associated with enhanced digestive action of gastric acid on the new granulation tissue at the ulcer base as a result of celecoxib-stimulated gastric acid secretion of the parietal cells." | 3.74 | [Selective COX-2 inhibitor delays experimental gastric ulcer healing by stimulating gastric acid secretion in rats]. ( He, MR; Lin, JQ; Song, YG, 2007) |
| "The study of the E2 and F2alpha (prostaglandins levels in the blood and mucous coat of the stomach was conducted in 20 patients with stomach ulcer, 15 patients with osteoarthritis taking diclofenac and 16 patients taking celecoxib." | 3.73 | [Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs]. ( Kolomiets, EV; Lazebnik, LB; Tkachenko, VN, 2005) |
| " In the present study we have compared the expression profile of COX-2 protein, prostaglandin E2 (PGE2) levels and myeloperoxidase activity in acetic acid induced chronic gastric ulcer model in rats treated with omeprazole, misoprostol and COX-2 selective nonsteroidal anti-inflammatory drug (NSAID) celecoxib." | 3.73 | Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing. ( Gautam, P; Poonam, D; Vinay, CS, 2005) |
| " Dose dependent percent inhibition of granuloma formation, exudate volume, total leukocyte count was observed in 4e (25, 50 and 100 mg/kg) and celecoxib (CAS 169590-42-5; 5 mg/kg) treated groups in the cotton pellet granuloma and granuloma pouch technique, respectively, in rats." | 3.73 | Evaluation of anti-inflammatory and analgesic activity of a new class of biphenyl analogs in animal models of inflammation. ( Bodhankar, SL; Kulkarni, VM; Rathi, BS; Wagh, NK, 2006) |
| "Celecoxib and indometacin both decreased the epithelial proliferative response and delayed healing of cryoprobe-induced gastric ulcers." | 3.71 | Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats. ( Bjarnason, I; Caldwell, C; Palmer, RH; Sigthorsson, G; Tibble, J, 2001) |
| "In 5 random groups of Wistar rats (n = 15 for each group), ulcerogenic doses of NSAIDs COX-1-COX-2 inhibitors such as indomethacin were compared with Celecoxib (COX-2 inhibitor); the production of antrum gastric ulcers and bowel and colon necrotic areas was studied." | 3.70 | [Celecoxib vs indomethacin and acute gastric lesions in rats]. ( Aramberry, LJ; Cesolari, JA; Esnarriaga, JM; Laudanno, OM; Maglione, CB; Piombo, G; Rista, L; Sambrano, JS, 2000) |
| "Celecoxib was associated with a lower risk of clinically significant upper and/or lower GI events than nsNSAIDs." | 2.78 | GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. ( Berger, MF; Cryer, B; Li, C; Simon, LS; Singh, G; Stillman, MJ, 2013) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| "We found that gastric cancer had significantly high expression of H." | 1.42 | Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study. ( Aziz, F; Wang, X; Yan, Q; Yang, X, 2015) |
| "Pretreatment with naproxen in the WRS model caused an increase in severity of damage and a decrease in NOS activity." | 1.40 | Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage. ( Biletska, L; Bondarchuk, T; Fomenko, I; Panasyuk, N; Sklyarov, A; Wallace, JL, 2014) |
| "Misoprostol did not produce any damage to the stomach." | 1.34 | Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats. ( Déciga-Campos, M; Granados-Soto, V; Medina-Santillan, R; Reyes-García, G, 2007) |
| "Celecoxib is a frequently used nonsteroidal anti-inflammatory drug (NSAID) in the treatment of rheumatoid arthritis and osteoarthritis." | 1.34 | The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats. ( Batu, OS; Erol, K, 2007) |
| "Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0." | 1.33 | Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. ( Fukunaga, M; Hayashi, A; Kimoto, A; Kobayashi, S; Miyata, K; Noguchi, M; Sasamata, M; Yoshino, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (3.70) | 18.2507 |
| 2000's | 47 (58.02) | 29.6817 |
| 2010's | 26 (32.10) | 24.3611 |
| 2020's | 5 (6.17) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, SS | 1 |
| Byun, Y | 1 |
| Lim, KM | 1 |
| Choi, JK | 1 |
| Lee, KW | 1 |
| Moh, JH | 1 |
| Kim, JK | 1 |
| Jeong, YS | 1 |
| Kim, JY | 1 |
| Choi, YH | 1 |
| Koh, HJ | 1 |
| Park, YH | 1 |
| Oh, YI | 1 |
| Noh, MS | 1 |
| Chung, S | 1 |
| Chhabria, MT | 1 |
| Bhatt, HG | 1 |
| Raval, HG | 1 |
| Oza, PM | 1 |
| Wey, SJ | 1 |
| Augustyniak, ME | 1 |
| Cochran, ED | 1 |
| Ellis, JL | 1 |
| Fang, X | 1 |
| Garvey, DS | 1 |
| Janero, DR | 1 |
| Letts, LG | 1 |
| Martino, AM | 1 |
| Melim, TL | 1 |
| Murty, MG | 1 |
| Richardson, SK | 1 |
| Schroeder, JD | 1 |
| Selig, WM | 1 |
| Trocha, AM | 1 |
| Wexler, RS | 1 |
| Young, DV | 1 |
| Zemtseva, IS | 1 |
| Zifcak, BM | 1 |
| Szabó, G | 1 |
| Fischer, J | 1 |
| Kis-Varga, A | 1 |
| Gyires, K | 1 |
| Akhter, M | 1 |
| Akhter, N | 1 |
| Alam, MM | 1 |
| Zaman, MS | 1 |
| Saha, R | 1 |
| Kumar, A | 2 |
| Manivannan, E | 1 |
| Chaturvedi, SC | 1 |
| Yamakawa, N | 1 |
| Suemasu, S | 1 |
| Okamoto, Y | 1 |
| Tanaka, K | 1 |
| Ishihara, T | 1 |
| Asano, T | 1 |
| Miyata, K | 3 |
| Otsuka, M | 1 |
| Mizushima, T | 1 |
| Abdel-Aziz, M | 2 |
| Beshr, EA | 1 |
| Abdel-Rahman, IM | 1 |
| Ozadali, K | 1 |
| Tan, OU | 1 |
| Aly, OM | 1 |
| Bansal, S | 1 |
| Bala, M | 1 |
| Suthar, SK | 1 |
| Choudhary, S | 1 |
| Bhattacharya, S | 1 |
| Bhardwaj, V | 1 |
| Singla, S | 1 |
| Joseph, A | 1 |
| Abuo-Rahma, Gel-D | 1 |
| Farag, NA | 1 |
| Kaoud, TS | 1 |
| Abdellatif, KR | 3 |
| Abdelgawad, MA | 3 |
| Elshemy, HA | 2 |
| Alsayed, SS | 2 |
| Undare, SS | 1 |
| Valekar, NJ | 1 |
| Patravale, AA | 1 |
| Jamale, DK | 1 |
| Vibhute, SS | 1 |
| Walekar, LS | 1 |
| Kolekar, GB | 1 |
| Deshmukh, MB | 1 |
| Anbhule, PV | 1 |
| Ali, Y | 1 |
| Alam, MS | 1 |
| Hamid, H | 1 |
| Husain, A | 1 |
| Dhulap, A | 1 |
| Bano, S | 1 |
| Kharbanda, C | 1 |
| Singh, J | 1 |
| Saini, V | 1 |
| Bansal, R | 1 |
| Navarro, L | 1 |
| Rosell, G | 1 |
| Sánchez, S | 1 |
| Boixareu, N | 1 |
| Pors, K | 1 |
| Pouplana, R | 1 |
| Campanera, JM | 1 |
| Pujol, MD | 1 |
| Ahmed, EM | 1 |
| Kassab, AE | 2 |
| El-Malah, AA | 1 |
| Hassan, MSA | 1 |
| Gedawy, EM | 1 |
| El Kerdawy, AM | 1 |
| Al-Ostoot, FH | 1 |
| Grisha, S | 1 |
| Mohammed, YHE | 1 |
| Vivek, HK | 1 |
| Ara Khanum, S | 1 |
| Khan, A | 1 |
| Diwan, A | 1 |
| Thabet, HK | 1 |
| Imran, M | 1 |
| Fadaly, WAA | 2 |
| Elshaier, YAMM | 2 |
| Hassanein, EHM | 1 |
| Abdellatif, KRA | 2 |
| Ragab, FAE | 1 |
| Mohammed, EI | 1 |
| Abdel Jaleel, GA | 1 |
| Selim, AAMAE | 1 |
| Nissan, YM | 1 |
| Fidahic, M | 1 |
| Jelicic Kadic, A | 1 |
| Radic, M | 1 |
| Puljak, L | 1 |
| Drmic, D | 1 |
| Kolenc, D | 1 |
| Ilic, S | 1 |
| Bauk, L | 1 |
| Sever, M | 1 |
| Zenko Sever, A | 1 |
| Luetic, K | 1 |
| Suran, J | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Bakr, RB | 2 |
| El-Gendy, AO | 1 |
| Kamel, GM | 2 |
| Azouz, AA | 2 |
| Bukhari, SNA | 1 |
| El-Magd, MA | 1 |
| Yonezawa, Y | 1 |
| Kihara, T | 1 |
| Ibi, K | 1 |
| Senshu, M | 1 |
| Nejishima, H | 1 |
| Takeda, Y | 1 |
| Imai, K | 1 |
| Ogawa, H | 1 |
| Küçükgüzel, ŞG | 1 |
| Coşkun, İ | 1 |
| Aydın, S | 1 |
| Aktay, G | 1 |
| Gürsoy, Ş | 1 |
| Çevik, Ö | 1 |
| Özakpınar, ÖB | 1 |
| Özsavcı, D | 1 |
| Şener, A | 1 |
| Kaushik-Basu, N | 1 |
| Basu, A | 1 |
| Talele, TT | 1 |
| Fomenko, I | 1 |
| Sklyarov, A | 1 |
| Bondarchuk, T | 1 |
| Biletska, L | 1 |
| Panasyuk, N | 1 |
| Wallace, JL | 2 |
| Aziz, F | 1 |
| Yang, X | 1 |
| Wang, X | 1 |
| Yan, Q | 1 |
| Kamel, G | 1 |
| Kanbayashi, Y | 1 |
| Konishi, H | 1 |
| Reyes-García, G | 1 |
| Déciga-Campos, M | 1 |
| Medina-Santillan, R | 1 |
| Granados-Soto, V | 1 |
| Sharma, SS | 1 |
| Srinivasan, SK | 1 |
| Krishnamoorthy, S | 1 |
| Kaushal, AM | 1 |
| Bansal, AK | 1 |
| Chung, MC | 1 |
| dos Santos, JL | 1 |
| Oliveira, EV | 1 |
| Blau, L | 1 |
| Menegon, RF | 1 |
| Peccinini, RG | 1 |
| Tsuji, S | 1 |
| Miyoshi, H | 1 |
| Tomita, T | 1 |
| Nakase, T | 1 |
| Hamada, M | 1 |
| Oomae, T | 1 |
| Tsumoto, C | 1 |
| Hirata, Y | 1 |
| Iguchi, M | 1 |
| Edogawa, S | 1 |
| Kawai, H | 1 |
| Yoshikawa, H | 1 |
| Chatterjee, A | 1 |
| Chatterjee, S | 1 |
| Das, S | 1 |
| Saha, A | 1 |
| Chattopadhyay, S | 1 |
| Bandyopadhyay, SK | 1 |
| Cryer, B | 2 |
| Li, C | 1 |
| Simon, LS | 2 |
| Singh, G | 1 |
| Stillman, MJ | 1 |
| Berger, MF | 2 |
| Wooltorton, E | 1 |
| Atkinson, HG | 1 |
| Kato, S | 1 |
| Ogawa, Y | 1 |
| Kanatsu, K | 1 |
| Okayama, M | 1 |
| Watanabe, T | 1 |
| Arakawa, T | 1 |
| Takeuchi, K | 1 |
| Chan, FK | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wu, JC | 1 |
| Lee, KC | 1 |
| Leung, VK | 1 |
| Hui, AJ | 1 |
| To, KF | 1 |
| Leung, WK | 1 |
| Wong, VW | 1 |
| Chung, SC | 1 |
| Sung, JJ | 1 |
| Zeidler, H | 2 |
| Chaabouni, H | 1 |
| Amouri, A | 1 |
| Cheikh, I | 1 |
| Kchaou, M | 1 |
| Ouerghi, H | 1 |
| Ben Mami, N | 1 |
| Ben Ammar, A | 1 |
| Saukkonen, K | 1 |
| Tomasetto, C | 1 |
| Narko, K | 1 |
| Rio, MC | 1 |
| Ristimäki, A | 1 |
| Perini, R | 1 |
| Fiorucci, S | 2 |
| Di Lorenzo, A | 1 |
| Renga, B | 1 |
| Farneti, S | 1 |
| Morelli, A | 1 |
| Cirino, G | 1 |
| Berenguer, B | 2 |
| Alarcón De La Lastra, C | 2 |
| Motilva, V | 1 |
| La Casa, C | 1 |
| Herrerias, JM | 1 |
| Pozo, D | 1 |
| Calero, MJ | 1 |
| Noguchi, M | 2 |
| Kimoto, A | 2 |
| Kobayashi, S | 2 |
| Yoshino, T | 2 |
| Sasamata, M | 2 |
| Kim, JH | 1 |
| Rhee, HI | 1 |
| Jung, IH | 1 |
| Ryu, K | 1 |
| Jung, K | 1 |
| Han, CK | 1 |
| Kwak, WJ | 1 |
| Cho, YB | 1 |
| Joo, HJ | 1 |
| Lazebnik, LB | 1 |
| Tkachenko, VN | 1 |
| Kolomiets, EV | 1 |
| Fukunaga, M | 1 |
| Hayashi, A | 1 |
| Poonam, D | 1 |
| Vinay, CS | 1 |
| Gautam, P | 1 |
| Goldstein, JL | 4 |
| Lowry, SC | 1 |
| Lanza, FL | 2 |
| Schwartz, HI | 1 |
| Dodge, WE | 2 |
| Rathi, BS | 1 |
| Wagh, NK | 1 |
| Bodhankar, SL | 1 |
| Kulkarni, VM | 1 |
| Gambero, A | 1 |
| Maróstica, M | 1 |
| Becker, TL | 1 |
| Pedrazzoli, J | 1 |
| Lichtenberger, LM | 1 |
| Romero, JJ | 1 |
| Dial, EJ | 1 |
| He, MR | 1 |
| Lin, JQ | 1 |
| Song, YG | 1 |
| Aisenberg, J | 1 |
| Zakko, SF | 1 |
| Amer, F | 1 |
| Hunt, B | 1 |
| Batu, OS | 1 |
| Erol, K | 1 |
| Lipsky, PE | 1 |
| Hubbard, RC | 1 |
| Talwalker, S | 1 |
| Schwartz, BD | 1 |
| Isakson, PC | 1 |
| Geis, GS | 1 |
| Mohammed, S | 1 |
| Croom, DW | 1 |
| Hinz, B | 1 |
| Brune, K | 1 |
| Laudanno, OM | 2 |
| Cesolari, JA | 2 |
| Esnarriaga, J | 1 |
| Rista, L | 2 |
| Piombo, G | 2 |
| Maglione, C | 1 |
| Aramberry, LJ | 2 |
| Sambrano, JS | 2 |
| Godoy, A | 1 |
| Rocaspana, A | 1 |
| Elias, M | 1 |
| Esnarriaga, JM | 1 |
| Maglione, CB | 1 |
| Kremer, J | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 1 |
| Rask-Madsen, J | 1 |
| Gottlieb, S | 2 |
| Bannwarth, B | 1 |
| Tibble, J | 1 |
| Sigthorsson, G | 1 |
| Caldwell, C | 1 |
| Palmer, RH | 1 |
| Bjarnason, I | 1 |
| Hawkey, CJ | 1 |
| Moreno, FJ | 1 |
| Martín, MJ | 1 |
| Jüni, P | 1 |
| Rutjes, AW | 1 |
| Dieppe, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In O[NCT00373685] | Phase 4 | 8,067 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.[NCT00594867] | Phase 4 | 94 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taki[NCT00175032] | Phase 3 | 1,045 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299] | Phase 2 | 120 participants | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00373685)
Timeframe: Baseline and Week 24 or ET
| Intervention | g/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -0.109 |
| nsNSAIDs | -0.241 |
(NCT00373685)
Timeframe: Baseline and Week 24 or ET
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.330 |
| nsNSAIDs | -0.716 |
(NCT00373685)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Celecoxib | 40.8 |
| nsNSAIDs | 40.9 |
(NCT00373685)
Timeframe: Baseline
| Intervention | gram per deciliter (g/dL) (Mean) |
|---|---|
| Celecoxib | 13.6 |
| nsNSAIDs | 13.6 |
GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 2.8 |
| nsNSAIDs | 3.0 |
CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin. (NCT00373685)
Timeframe: Baseline through week 24 or Early Termination (ET)
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 1.3 |
| nsNSAIDs | 2.4 |
"Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function." (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 2.3 |
| nsNSAIDs | 3.4 |
Positive blood fecal occult; blood in feces that is not visibly apparent (NCT00373685)
Timeframe: Week 24 or ET
| Intervention | Percentage of participants (Number) |
|---|---|
| Celecoxib | 1.1 |
| nsNSAIDs | 1.4 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3888, 3905) | Week 8 (n=3185, 3203) | Week 16 (n=2783, 2778) | Week 24 or ET (n=3385, 3362) | Week 24/LOCF (n=3671, 3653) | |
| Celecoxib | 41.4 | 77.4 | 80.5 | 74.0 | 74.0 |
| nsNSAIDs | 40.5 | 69.2 | 74.5 | 71.3 | 70.8 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3886, 3905) | Week 8 (n=3182, 3202) | Week 16 (n=2780,2778) | Week 24 or ET (n=3383,3361) | Week 24/LOCF (n=3671, 3653) | |
| Celecoxib | 37.8 | 75.4 | 77.8 | 72.2 | 72.2 |
| nsNSAIDs | 36.6 | 66.8 | 71.6 | 68.8 | 68.2 |
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15. (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3890, 3905) | Week 8 (n=3185, 3202) | Week 16 (n=2784,2777) | Week 24 or ET (n=3386,3362) | Week 24/LOCF (n=3672, 3653) | |
| Celecoxib | 43.2 | 80.2 | 83.2 | 76.2 | 76.0 |
| nsNSAIDs | 43.7 | 71.6 | 77.7 | 73.8 | 73.3 |
Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline (n=3887, 3904) | Week 8 (n=3181, 3199) | Week 16 (n=2784, 2772) | Week 24 or ET (n=3383, 3361) | Week 24/LOCF (n=3672, 3651) | |
| Celecoxib | 39.8 | 78.5 | 81.9 | 74.6 | 74.5 |
| nsNSAIDs | 38.0 | 69.5 | 74.6 | 70.8 | 70.3 |
Clinically significant decrease in Hct (greater than or equal to 10 percent [≥10%]) and/or decrease in Hb (≥ 2 g/dL). (NCT00373685)
Timeframe: Baseline, Weeks 8, 16, 24 or ET
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 8 (n= 3043, 3086) | Week 16 (n=2687, 2675) | Week 24 (n=3278, 3207) | Week 24 LOCF (n=3604, 3574) | |
| Celecoxib | 0.7 | 0.8 | 0.9 | 1.8 |
| nsNSAIDs | 0.9 | 1.6 | 1.5 | 2.9 |
Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use. (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Acetaminophen | Acetylsalicylic acid (ASA) | NSAIDs | Opioids | |
| Celecoxib | 6.8 | 3.5 | 12.8 | 14.2 |
| nsNSAIDs | 6.5 | 3.0 | 13.3 | 15.6 |
PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists [H2RA], misoprostol, sucralfate, and others such as antacids) utilization. (NCT00373685)
Timeframe: Baseline through week 24 or ET
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| PPIs | H2RAs | Gastric protective agents | |
| Celecoxib | 23.0 | 5.0 | 0.9 |
| nsNSAIDs | 24.2 | 5.7 | 1.0 |
8 reviews available for celecoxib and Gastric Ulcer
| Article | Year |
|---|---|
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Myocardial Infarc | 2017 |
[Selective cyclooxygenase-2 inhibitors and the digestive tract].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestiv | 2002 |
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc | 2004 |
From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2000 |
Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Hum | 2000 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
Cyclooxygenase inhibition: between the devil and the deep blue sea.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2002 |
6 trials available for celecoxib and Gastric Ulcer
| Article | Year |
|---|---|
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibi | 2013 |
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Doub | 2006 |
Endoscopic ulcer rates in healthy subjects associated with use of aspirin (81 mg q.d.) alone or coadministered with celecoxib or naproxen: a randomized, 1-week trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy | 2008 |
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas | 2007 |
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors | 1998 |
67 other studies available for celecoxib and Gastric Ulcer
| Article | Year |
|---|---|
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
Topics: Adult; Animals; Arthritis, Experimental; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2004 |
Synthesis and biological evaluation of some 5-ethoxycarbonyl-6-isopropylamino-4-(substitutedphenyl)aminopyrimidines as potent analgesic and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemical Phenomena; Chemistry, Physical; Indicator | 2007 |
Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Drug Synergism; Female; Gastr | 2007 |
New celecoxib derivatives as anti-inflammatory agents.
Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy | 2008 |
Synthesis and biological evaluation of 2,5-disubstituted 1,3,4-oxadiazole derivatives with both COX and LOX inhibitory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Edema; Enzyme Inhibitors; Lipid Perox | 2011 |
Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase I | 2011 |
Synthesis and biological evaluation of derivatives of 2-{2-fluoro-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low gastric ulcerogenic activity.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; | 2012 |
1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.
Topics: Animals; Anisoles; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxyg | 2014 |
Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclo | 2014 |
Novel 1-[4-(Aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry Techniques, Synthetic; Cyclooxygenase 2; | 2014 |
Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 I | 2016 |
Synthesis, anti-inflammatory, ulcerogenic and cyclooxygenase activities of indenopyrimidine derivatives.
Topics: Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Binding Sites; Carrageenan; Catalytic Domain; | 2016 |
Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening.
Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Anti-Inflammatory Agents; Drug Design; Rats; Rats, Wistar; | 2017 |
Synthesis, molecular docking and biological evaluation of some newer 2-substituted-4-(benzo[d][1,3]dioxol-5-yl)-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analgesic agents.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Carrageenan; Cyclooxy | 2017 |
Synthesis and biological properties of aryl methyl sulfones.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimet | 2018 |
Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 In | 2019 |
Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Arachidonate 5-Lipoxygenase; Cyclo | 2020 |
Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeic Acids; Carrageena | 2021 |
Synthesis of novel N-substitutedphenyl-6-oxo-3-phenylpyridazine derivatives as cyclooxygenase-2 inhibitors.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Edema; Female; | 2020 |
New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide relea
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Celecoxib; Cell | 2020 |
Synthesis of Hydroxybenzofuranyl-pyrazolyl and Hydroxyphenyl-pyrazolyl Chalcones and Their Corresponding Pyrazoline Derivatives as COX Inhibitors, Anti-inflammatory and Gastroprotective Agents.
Topics: Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Binding Sites; Catalytic Domain; Celecoxib; | 2020 |
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.
Topics: Animals; Anti-Ulcer Agents; Antidotes; Arginine; Brain; Celecoxib; Chemical and Drug Induced Liver I | 2017 |
Discovery of a COX-2 selective inhibitor hit with anti-inflammatory activity and gastric ulcer protective effect.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Discovery; | 2017 |
Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors.
Topics: alpha-Glucosidases; Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cellulases; Cycl | 2019 |
Olive-Derived Hydroxytyrosol Shows Anti-inflammatory Effect without Gastric Damage in Rats.
Topics: Animals; Aspirin; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Gastric | 2019 |
Synthesis and characterization of celecoxib derivatives as possible anti-inflammatory, analgesic, antioxidant, anticancer and anti-HCV agents.
Topics: Animals; Antineoplastic Agents; Antioxidants; Antiviral Agents; Catalytic Domain; Celecoxib; Cell Li | 2013 |
Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Celecoxib; Disease Models, Animal; Epi | 2014 |
Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cycl | 2015 |
Synthesis and anti-inflammatory evaluation of new 1,3,5-triaryl-4,5-dihydro-1H-pyrazole derivatives possessing an aminosulphonyl pharmacophore.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Inf | 2015 |
Predictive Factors for NSAIDs-related Gastrointestinal Toxicity: Can COX-2 Selective Inhibtor Prevent it?.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplast | 2015 |
Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4-d]pyrimidine derivatives.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxy | 2016 |
Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2 Inh | 2007 |
Preclinical safety pharmacological studies on the amorphous formulation of celecoxib.
Topics: Animals; Behavior, Animal; Blood Pressure; Celecoxib; Chemistry, Pharmaceutical; Cyclooxygenase 2 In | 2009 |
Synthesis, ex vivo and in vitro hydrolysis study of an indoline derivative designed as an anti-inflammatory with reduced gastric ulceration properties.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Celecoxib; Diclofenac; Drug Design; Hydrolysis; Indo | 2009 |
Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 In | 2012 |
Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation.
Topics: Animals; Blotting, Western; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors | 2012 |
[Coxib spares the stomach. This is true also for patients with preventive aspirin administration].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Drug Therapy, Co | 2002 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2002 |
Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis.
Topics: Animals; Arthritis, Experimental; Capillary Permeability; Celecoxib; Cyclooxygenase 1; Cyclooxygenas | 2002 |
[When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxi | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Topics: Adenoma; Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cy | 2004 |
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2004 |
Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat.
Topics: Animals; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2005 |
[Role of prostaglandins in the pathogenesis of stomach ulcer and gastropathy caused by non-steroid anti-inflammatory drugs].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; | 2005 |
Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2005 |
Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.
Topics: Animals; Anti-Ulcer Agents; Blotting, Western; Celecoxib; Chronic Disease; Cyclooxygenase 2; Dinopro | 2005 |
Evaluation of anti-inflammatory and analgesic activity of a new class of biphenyl analogs in animal models of inflammation.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; C-Rea | 2006 |
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; D | 2007 |
Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin.
Topics: Animals; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Drug Interactions; Gastric Muc | 2007 |
[Selective COX-2 inhibitor delays experimental gastric ulcer healing by stimulating gastric acid secretion in rats].
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastric Acid; Gene Expression Regulation, Enzymolog | 2007 |
The effects of some nonsteroidal anti-inflammatory drugs on experimental induced gastric ulcers in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Dinoprosto | 2007 |
Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; | 1999 |
[Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2000 |
[Gastrointestinal damage induced by celecoxib and rofecoxib in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Disease Mode | 2000 |
Gastropathy and NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Drug Labeling; Female; Humans; Pyrazoles; Risk F | 2000 |
COX-2 inhibitors and Celebrex: safe or suspect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
[Celecoxib vs indomethacin and acute gastric lesions in rats].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Digestive Sy | 2000 |
FDA refuses companies' request to drop ulcer warning.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Labeling; | 2001 |
Researchers deny any attempt to mislead the public over JAMA article on arthritis drug.
Topics: Antirheumatic Agents; Celecoxib; Clinical Trials as Topic; Drug Approval; Fraud; Humans; Information | 2001 |
[New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
Topics: Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase I | 2001 |
Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cell Division; Cyclooxygenas | 2001 |
Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; | 2002 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase | 2002 |